Phaseline

Companies › Benitec Biopharma

Benitec Biopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Nov 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BB-301
AAV9-delivered gene therapy encoding codon-optimized wildtype PABPN1 protein and 2 shRNAs
PABPN1Phase 1Oculopharyngeal Muscular DystrophyNov 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06185673BB-301Phase 1Oculopharyngeal Muscular DystrophyNeurologyNov 2030

From the company's SEC filings

Cash of $180m on 2026-06-30; operating cash outflow about $17m a year; runway about 130 months at that burn, to May 2037

Press releases filed as 8-K in the last year:

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PABPN1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.